{{Rsnum
|rsid=12113878
|Gene=KLRG2
|Chromosome=7
|position=139458699
|Orientation=plus
|GMAF=0.2801
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;G)
|geno3=(G;G)
|Gene_s=KLRG2
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;G)
| geno3=(G;G)
| CEU | 63.7 | 31.0 | 5.3
| HCB | 44.5 | 40.9 | 14.6
| JPT | 52.3 | 34.2 | 13.5
| YRI | 52.4 | 42.9 | 4.8
| ASW | 52.6 | 36.8 | 10.5
| CHB | 44.5 | 40.9 | 14.6
| CHD | 40.4 | 35.8 | 23.9
| GIH | 52.0 | 38.0 | 10.0
| LWK | 34.5 | 50.0 | 15.5
| MEX | 55.2 | 37.9 | 6.9
| MKK | 48.7 | 41.0 | 10.3
| TSI | 51.0 | 40.2 | 8.8
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs12113878
|Name_s=
|Gene_s=KLRG2
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 89. Study population/ethnicity: 89 Yorubans. Significance metric(s): p = 0.00009. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109386
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs12113878
|overall_frequency_n=43
|overall_frequency_d=128
|overall_frequency=0.335938
|n_genomes=30
|n_genomes_annotated=0
|n_haplomes=39
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}